enGene Therapeutics (ENGNW) reported a net loss attributable to common shareholders of $32.5 million, or $0.47 per basic and diluted share, for the three months ended July 31, 2026. The company ended the quarter with $266.3 million in cash, cash equivalents and marketable securities.
The company said it plans to provide an update from the pivotal LEGEND Cohort 1, hold a pre-BLA meeting with the FDA, and initiate a biologics license application for detalimogene in the fourth quarter of 2026.
- Total operating expenses were $34.0 million, compared with $29.9 million a year earlier.
- Research and development expense was $20.1 million, while general and administrative expense was $13.9 million.
- LEGEND Cohort 1 previously reported a 54% complete response rate at any time and a 3.2% progression rate to muscle-invasive disease.
- enGene plans a webinar on surfactant plus detalimogene preclinical data and cohort enrollment guidance on October 15, 2026.
- The company said a potential FDA approval decision for detalimogene and platform designation are anticipated in 2027.
$ENGNW Hedge Fund Activity
We have seen 4 institutional investors add shares of $ENGNW stock to their portfolio, and 9 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPTION MANAGEMENT, LLC added 333,675 shares (+inf%) to their portfolio in Q2 2026, for an estimated $96,732
- VIVO CAPITAL, LLC removed 285,046 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $721,166
- CALAMOS ADVISORS LLC removed 148,290 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $375,173
- TENOR CAPITAL MANAGEMENT CO., L.P. removed 55,243 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $16,014
- SABA CAPITAL MANAGEMENT, L.P. removed 40,057 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $11,612
- ARISTEIA CAPITAL, L.L.C. added 33,167 shares (+20.2%) to their portfolio in Q2 2026, for an estimated $9,615
- TORONTO DOMINION BANK added 31,545 shares (+inf%) to their portfolio in Q2 2026, for an estimated $9,144
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
